PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a finished-dose generic company from the United States

Selling into Europe as a finished-dose generic company from the United States

Your generic filings reach European regulators complete, and your launch dates hold.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • United States, Finished-dose generic companywho it is written for

Why this training matters

Your regulatory team files a generic application in Europe, and a small procedural slip comes back as a list of questions. The product waits while the launch date passes and the quarter's target goes with it. Then someone explains the delay to the board.

What changes after this course

Your team picks the right procedure for each product's scope and files complete dossiers. Launches keep to plan. You hold a certificate for every learner and a training record for each person, backed by a recorded multiple-choice questionnaire per module.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory team stops asking legal which route a product takes. They read the scope and existing authorizations, choose the Centralized, Decentralized or Mutual Recognition Procedure, and send the file to the European Medicines Agency or the right national competent authority. When a reference member state is needed, they settle it before drafting starts, not after the first rejection.

In quality, Module 3 of the Common Technical Document comes together once. Active substance data matches the European Pharmacopoeia where a monograph exists, and the stability gap that draws deficiency letters is closed before filing. The Module 2.5 clinical overview carries the bioequivalence comparison the assessor looks for, and the Article 10 reference medicinal product is checked before anyone files.

Supply chain and compliance staff hand the Qualified Person a batch file that already answers Article 51 of Directive 2001/83/EC. Good Manufacturing Practice records sit ready for inspectors. The Pharmacovigilance System Master File is current, EudraVigilance reports go out on time, and each process change is filed as the Type IA, Type IB or Type II variation Commission Regulation (EC) No 1234/2008 requires.

Commercial managers stop copying one price list across borders. They build each submission for the national health technology assessment, work out who decides in each tender, and time the launch to the pharmacy. When an inspector walks in, staff answer from records, not from memory.

Who needs this training

  • Regulatory Affairs Manager, European Expansion

    Picks the filing route for a new generic and must settle the reference member state before the first draft, not after the application comes back with questions.

  • Head of Quality Assurance, European Operations

    Sits across from an inspector who asks for proof of European Union Good Manufacturing Practice compliance, and needs the records on the table, not a promise to send them later.

  • Supply Chain Director, European Imports

    Watches finished doses sit in quarantine because the Qualified Person will not certify until the batch documents match what Article 51 of Directive 2001/83/EC requires.

  • Pharmacovigilance Specialist, European Compliance

    Has a EudraVigilance reporting deadline coming and a Pharmacovigilance System Master File that must be correct before a regulator or inspector asks to see it.

  • Business Development Lead, International Markets

    Faces a national health technology assessment body or a tender panel and must justify the price of a generic in terms that country's payer accepts.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Finished-dose generic company

Countries: United States

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Select the marketing authorization procedure that fits a finished-dose generic's scope and name the regulator that receives the file.
  2. Lay out Module 3 of the Common Technical Document and check active substance data against the European Pharmacopoeia.
  3. Check the reference medicinal product cited under Article 10 of Directive 2001/83/EC before the application goes in.
  4. Assemble a batch file that answers the Qualified Person's checks under Article 51 of Directive 2001/83/EC.
  5. Classify a manufacturing change as Type IA, Type IB or Type II under Commission Regulation (EC) No 1234/2008.
  6. Prepare the Good Manufacturing Practice records an inspector asks for and answer questions from them.
  7. Shape a pricing submission for one country's health technology assessment instead of reusing a Europe-wide price.

What the company gets

  • Applications reach European regulators complete, so launch dates stop depending on how fast your team answers avoidable questions.
  • Every batch file arrives at the Qualified Person ready to sign, which shortens the time finished doses spend in quarantine.
  • Your Pharmacovigilance System Master File and variation filings stay current, so a regulator's request is answered from documents already in hand.
  • Inspectors get straight, documented answers from staff who know where each Good Manufacturing Practice record sits.
  • Your commercial team enters each country with a price and a tender plan built for that market.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Route each filing to the right European regulator

    • Why a dossier sent to the wrong regulator sits unread while your launch date slips.
    • How to tell which decisions sit with the European Medicines Agency and which with a national authority.
    • The map of who approves, who inspects and who prices that your team reuses for every product.
  2. 2Pick the right marketing authorization procedure for each generic product

    • How to pick the Centralized, Decentralized or Mutual Recognition route from your product's scope and existing authorizations.
    • What to do when your filing needs a reference member state and you have not settled on one.
    • When a Decentralized filing beats a Centralized one, and when it costs you a launch window.
  3. 3Build Module 3 of the Common Technical Document for fast approval

    • How to lay out Module 3 so a reviewer finds each answer where the Common Technical Document puts it.
    • The stability data gap that draws a deficiency letter, and how to close it before you file.
    • Why your active substance data must match the European Pharmacopoeia wherever a monograph exists.
  4. 4Draft non-clinical and clinical overviews that support your generic

    • How to write the Module 2.4 and 2.5 overviews so they lean on the reference product's record.
    • The bioequivalence comparison reviewers look for first, and where it sits in the clinical overview.
    • What to do when your clinical overview leaves out a comparison the assessor expects.
  5. 5File a complete generic application under Article 10 of Directive 2001/83/EC

    • How to use the abridged route under Article 10 of Directive 2001/83/EC to skip studies you do not need.
    • Why a wrong reference medicinal product in your Article 10 application puts the whole file at risk.
    • The final check that catches the small procedural slips behind a long list of questions.
  6. 6Hold European Union Good Manufacturing Practice standards at every site

    • How to show a European inspector that your sites meet Good Manufacturing Practice before they ask.
    • The documents an inspector asks for first, and how to keep them ready at each site.
    • What happens to a batch at the border when proof of compliant manufacture is missing.
  7. 7Clear importation and batch release under Article 51 of Directive 2001/83/EC

    • How to build a batch file your Qualified Person can sign without sending it back.
    • The duties Article 51 of Directive 2001/83/EC gives your Qualified Person, and the papers behind each.
    • Why one missing import document leaves finished doses in quarantine, and how to stop it.
  8. 8Build your Pharmacovigilance System Master File and EudraVigilance routine

    • How to structure your Pharmacovigilance System Master File so it answers an inspector's first question.
    • The reporting duties to EudraVigilance that keep your product on the market, and when they fall due.
    • What to report, to whom and by when, so a missed report does not become a regulatory penalty.
  9. 9Classify and submit variations under Commission Regulation (EC) No 1234/2008

    • How to sort any change into Type IA, Type IB or Type II before you commit to a filing.
    • The steps Commission Regulation (EC) No 1234/2008 sets for each type, in the order you follow them.
    • Why a manufacturing change made before the approval it needs puts your marketing authorization at risk.
  10. 10Set generic pricing and reimbursement for each national market

    • How to shape each pricing submission to the health technology assessment of that country.
    • The national reimbursement rules that decide whether doctors prescribe your generic at all.
    • Why one pricing plan for all of Europe closes doors you could have opened.
  11. 11Execute a country-by-country commercial strategy for your generic

    • How to prepare for a national tender so your offer is read, not set aside.
    • The people you must pitch in each country, from payer to pharmacy, before your launch date.
    • What to do when pharmacists pass over your generic because your launch timing was wrong.
  12. 12Pass European regulatory inspections and audits with records in hand

    • How to answer a hard inspector question with a document, not an opinion.
    • The Good Manufacturing Practice records to keep within reach for an inspector who arrives without notice.
    • Why a failed inspection puts your marketing authorization and supply at risk, and what stops it.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for United States, Finished-dose generic company. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team